Lilly vows appeal of Alimta patent ruling in Germany
This article was originally published in Scrip
Eli Lilly will try to overturn the German Court of Appeal's ruling that its vitamin regimen patent for Alimta (pemetrexed) will not be infringed when Actavis launches a dipotassium salt form of pemetrexed after the cancer drug's compound patent expires in Germany in December.
You may also be interested in...
Eli Lilly & Co.'s first quarter earnings met analyst expectations with help from recently approved products, but greater growth in future years depends on a closely-watched Phase III Alzheimer's program.
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.